Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Rayno Biopharmaceutical Stocks Q1 2014 Performance

|Includes:AbbVie Inc. (ABBV), ARIA, GILD

Rayno Biopharmaceutical Portfolio 3/31/14

Most of our biotech picks did well in a tough quarter that went through a severe correction in early February and again in late March. Many small and mid-cap momentum stocks were crushed but indices (FBT,IBB) overall held the early February technical levels. Use the two ETFs and FBIOX for re-balancing portfolios.

Our top winners for the first quarter were :

Albany Molecular (NASDAQ:AMRI) up 81%!, Alexion (NASDAQ:ALXN) up 14.3%, Seattle Genetics (NASDAQ:SGEN) up 11.6%, and Alkermes (NASDAQ:ALKS) up 10.2%.

The top losers were:

Pharmacyclics (NASDAQ:PCYC) down 5.7%, Gilead Sciences (NASDAQ:GILD) down 5.5% and Vertex (NASDAQ:VRTX) down 4.9%.

We added three new stocks: Abbvie (NYSE:ABBV) an Abbott spin-off large cap biotech, Ariad (ARIA a small cap biotech and ROCHE Holdings (OTCQX:RHHBY) a leading large cap drug and diagnostic Company. We also recommended increasing the cash position to 20% early in the corrective phase. Keep in mind that most biotech stocks were up about 60% in 2013.

Biotech stocks are now in a two day rally moving many stocks up 5%. We will review our diagnostic and tools portfolio later this week.

Rayno Biopharmaceutical Picks

2014   Original P Price Price Price % Ret Price % Ret  
Summary Ticker Recomm   Apr'11 Dec'12 Nov'13 11/1/13 3/31/14 YTD  
                     
Abbvie ABBV 3/25/14 51.7 new       51.4 0  
Achillion ACHN 3/4/13 8.6 new   2.53 -68 3.3 -1.5  
Alexion ALXN 2/2/09 35 100.8 95.4 123.4 2.26 153.13 14.3  
Alkermes ALKS 3/22/13 23 new 18.5 35.6 59.29 44.09 10.2  
Albany Mol AMRI 2/10/11 4.68 4.32 5.3 13.2 140.7 18.59 81  
Ariad ARIA 3/25/14 7.61 new       8.06 5.9  
Astex ASTX* 12/27/11 1.63   2.7 8.5 49.48 acq    
Amgen AMGN 2/2/09 55 54 87.4 118.7 13.1 123.34 8  
Biogen BIIB 2/2/09 48.5 73.25 149 243 48.85 305.87 9.4  
Cephalon CEPH* 2/2/09 76.5 76.92 80.18   30 acq    
Cubist CBST 2/2/09 21.5 28.35 42.4 61.9 19.2 73.15 6.3  
FT Arca ETF FBT 4/15/10 37.5 41.3 46 64.6 29.6 76.7 11  
Gilead GILD 2/2/09 51 42.8 72.7(s) 71 40.67 70.86 -5.5  
iShares ETF IBB 2/2/09 70.5 101.1 137.8 206 29.9 236.3 3.8  
Fido Biotech FBIOX             194.85 7.22  
ImmunoGen IMGN 12/22/11 12.4   12.5 16.3 34.8 14.93 1.9  
Optimer OPTR* 2/18/11 11.8 13.8 9.2 12.8 60 acq    
Pharmacycl PCYC 6/8/12 38.2   58 122 47.8 100.22 -5.7  
Regeneron REGN 2/2/09 17.5 45.43 173 286 34.5 300.28 9.1  
Roche ADR RHHBY 1/30/14 67 new       37.75(s) 7.7  
Seattle Gen. SGEN 2/2/09 9.5 15.72 23.3 39 41 45.56 11.6  
Vertex VRTX 11/15/13 62.8 new       70.65 -4.9  
ViroPharma VPHM* 2/2/09 12 20.05 22.9 39 29.4 acq    
                     
*acquired                    
Click to enlarge

Chart forFirst Trust NYSE Arca Biotech Index (NYSEARCA:<a href='http://seekingalpha.com/symbol/FBT' title='First Trust NYSE Arca Biotechnology Index ETF'>FBT</a>)

Disclosure: I am long ABBV, ARIA, GILD, ACHN.

Additional disclosure: Long FBIOX.

Stocks: ABBV, ARIA, GILD